Biocon Wins FDA Nod for Yesintek Autoinjectors in US

Biocon's supplemental approval for Yesintek prefilled autoinjectors from the US FDA extends the biosimilar's delivery portfolio and signals a broader lifecycle management strategy that QA directors and regulatory affairs leads in combination product manufacturing will recognise as increasingly standard practice for biosimilar programmes.

Yesintek, Biocon's biosimilar referencing Stelara (ustekinumab), was previously approved in vial and prefilled syringe formats. The addition of prefilled autoinjectors introduces a combination product classification layer, bringing 21 CFR Part 4 coordination requirements into scope alongside the existing biologics licence obligations. For manufacturing sites, that means device-drug integration controls, human factors validation, and container closure integrity testing must satisfy both CDER and CDRH expectations within a unified quality system aligned to ICH Q10.

The device component adds complexity at the fill-finish and assembly stages. Autoinjector platforms require tighter tolerances on fill volume, stopper placement, and activation force specifications than prefilled syringes, and any post-approval change to the device supplier or primary packaging must be managed through a Prior Approval Supplement. Plant heads running combination product lines will also need to confirm that their process validation protocols address the integrated system, not the drug product in isolation.

From a market access standpoint, the expanded format supports administration across outpatient and self-administration settings, which broadens the commercial footprint without requiring a new biologics licence application. For regulatory affairs teams, the approval demonstrates that the FDA is processing combination product supplements for biosimilars within a workable review cycle, a relevant data point as other sponsors plan similar lifecycle extensions for their own programmes.

The sterility assurance programme for prefilled autoinjectors assembled in a closed, automated environment will face scrutiny during any subsequent pre-approval inspection or surveillance visit, particularly around particulate control and container closure integrity at the device-drug interface.

Biocon's next measurable checkpoint is commercial launch sequencing for the autoinjector format, which will determine how quickly the expanded delivery option reaches dispensing channels and whether the approval translates into a measurable shift in Yesintek's formulary positioning against reference Stelara and competing ustekinumab biosimilars.

Source: Media4Growth via Indian Pharma Post, 17 August 2026.